| Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy |
| Ju Youn Lee1, Hee Kyung Jin1, Jae-sung Bae1,* |
1Alzheimer’s disease Research Institute, Kyungpook National University, Daegu 41566, Korea,
2Department of Physiology, School of Medicine, Kyungpook National University, Daegu 41944, Korea,
3Department of Biomedical Science, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 41944, Korea,
4Department of Laboratory Animal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Korea |
|
Abstract
Sphingolipids are ubiquitous building blocks of eukaryotic cell membranes that function as signaling molecules for regulating a diverse range of cellular processes, including cell proliferation, growth, survival, immune-cell trafficking, vascular and epithelial integrity, and inflammation. Recently, several studies have highlighted the pivotal role of sphingolipids in neuroinflammatory regulation. Sphingolipids have multiple functions, including induction of the expression of various inflammatory mediators and regulation of neuroinflammation by directly effecting the cells of the central nervous system. Accumulating evidence points to sphingolipid engagement in neuroinflammatory disorders, including Alzheimer’s and Parkinson’s diseases. Abnormal sphingolipid alterations, which involves an increase in ceramide and a decrease in sphingosine kinase, are observed during neuroinflammatory disease. These trends are observed early during disease development, and thus highlight the potential of sphingolipids as a new therapeutic and diagnostic target for neuroinflammatory diseases.
|
| Abstract, Accepted Manuscript [Submitted on November 11, 2019, Accepted on December 9, 2019] |
|